MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

Rhea-AI Summary

MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.

The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.

News Market Reaction – MDXG

-0.39%

1 alert

-0.39% News Effect

On the day this news was published, MDXG declined 0.39%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications

MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the 15^th anniversary of EPIFIX and AMNIOFIX, the Company’s placental allografts used in wound care and surgical recovery settings.

“We are thrilled to mark the 15^th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovation in the space,” stated Randall Spencer, MIMEDX Vice President, Clinical Innovation. “Over the years, MIMEDX has changed the paradigm of wound care treatment and surgical recovery. The Company’s products have become the placental allografts of choice across many specialties, including in over a dozen surgical fields, for their vast utility, handling characteristics, and robust peer-reviewed data. Together, EPIFIX and AMNIOFIX have been studied in almost 100 clinical and scientific publications which include seven randomized controlled trials, achieving recognition as the industry’s most studied placental allografts. We are grateful to all our dedicated employees who have made it possible for us to reach this milestone.”

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With over a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What milestone did MIMEDX (MDXG) announce on February 2, 2026?

MIMEDX announced the 15th anniversary of EPIFIX and AMNIOFIX, its flagship placental allografts. According to the company, the products have been studied in nearly 100 clinical and scientific publications, including seven randomized controlled trials, supporting broad clinical adoption.

How extensively have EPIFIX and AMNIOFIX been studied, according to MIMEDX (MDXG)?

EPIFIX and AMNIOFIX appear in almost 100 clinical and scientific publications, per the company. According to the company, that body of evidence includes seven randomized controlled trials and spans use across more than a dozen surgical specialties.

What clinical settings use MIMEDX’s EPIFIX and AMNIOFIX (MDXG)?

EPIFIX and AMNIOFIX are used in wound care and surgical recovery settings, the company said. According to the company, clinicians employ the allografts across over a dozen surgical fields for handling characteristics, versatility, and peer-reviewed clinical data.

Does MIMEDX (MDXG) claim EPIFIX and AMNIOFIX are the industry’s most studied placental allografts?

Yes; the company describes EPIFIX and AMNIOFIX as the industry’s most studied placental allografts. According to the company, that claim is grounded in nearly 100 publications and multiple randomized controlled trials.

What did MIMEDX say about future focus following the 15th anniversary announcement (MDXG)?

The company emphasized ongoing clinical innovation and gratitude to employees for reaching the milestone. According to the company, the anniversary highlights continued focus on supporting peer-reviewed research and clinical adoption across specialties using EPIFIX and AMNIOFIX.